SKLB023 protects against inflammation and apoptosis in sepsis-associated acute kidney injury via the inhibition of toll-like receptor 4 signaling
International Immunopharmacology · 2024
DOI: 10.1016/j.intimp.2024.112668 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Hui Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Institute of Kidney Diseases, West China Hospital of Sichuan University, Chengdu 610041, PR China. Hauptthemen laut MEDLINE: Acute Kidney Injury, Toll-Like Receptor 4, Sepsis, Apoptosis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Sichuan University, Sichuan Province Science and Technology Support Program.
Themen: Sepsis
Abstract (Originalsprache)
Sepsis-associated acute kidney injury (SA-AKI) is one of common critical illnesses with high morbidity and mortality. At present, effective therapeutic drugs for SA-AKI are remain lacking. SKLB023 is a synthetic small-molecule compound which exerts potent anti-inflammatory effects in our previous studies. Here, this study aimed to characterize the protective effect of SKLB023 on SA-AKI and explore its underlying mechanism. The SA-AKI experimental models have been established by cecum ligation/puncture (CLP) and lipopolysaccharide (LPS) injection in male C57BL/6J mice. SKLB023 was administered by gavage (50 or 25 mg/kg in CLP model and 50 mg/kg in LPS model) daily 3 days in advance and 30 min earlier on the day of modeling. Our results confirmed SKLB023 treatment could improve the survival of SA-AKI mice and ameliorate renal pathological injury, inflammation, and apoptosis in the two types of septic AKI mice. Mechanically, SKLB023 deceased the expression of TLR4 in LPS-triggered renal tubular epithelial cells, and inhibited the activation of downstream pathways including NF-κB and MAPK pathways. Our study suggested that SKLB023 is expected to be a potential drug for the prevention and treatment of septic AKI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Institute of Kidney Diseases, West China Hospital of Sichuan University, Chengdu 610041, PR China.
- Department of Medicine Renal Division, Affiliated Hospital & Clinical Medical College of Chengdu University, Chengdu 610041, PR China.
- West-district Outpatient Department, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, PR China. Electronic address: linlin_stomatology@foxmail.com.
- Department of Nephrology, Organ Transplant Center, Guizhou Province Key Laboratory of Cell Engineering, Affiliated Hospital of ZunYi Medical University, ZunYi 563003, PR China. Electronic address: tanzhouke@zmu.edu.cn.
- Department of Nephrology, Institute of Kidney Diseases, West China Hospital of Sichuan University, Chengdu 610041, PR China. Electronic address: liang_m@scu.edu.cn.
Förderung
- National Natural Science Foundation of China
- Sichuan University
- Sichuan Province Science and Technology Support Program
- China Postdoctoral Science Foundation
Zitieren
APA
Li, H., Ren, Q., Hu, Y., Guo, F., Huang, R., Lin, L., Tan, Z., Ma, L., & Fu, P. (2024). SKLB023 protects against inflammation and apoptosis in sepsis-associated acute kidney injury via the inhibition of toll-like receptor 4 signaling. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112668
Vancouver
Li H, Ren Q, Hu Y, Guo F, Huang R, Lin L, et al. SKLB023 protects against inflammation and apoptosis in sepsis-associated acute kidney injury via the inhibition of toll-like receptor 4 signaling. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112668
BibTeX
@article{Li2024,
author = {Li, Hui and Ren, Qian and Hu, Yao and Guo, Fan and Huang, Rongshuang and Lin, Lin and Tan, Zhouke and Ma, Liang and Fu, Ping},
title = {SKLB023 protects against inflammation and apoptosis in sepsis-associated acute kidney injury via the inhibition of toll-like receptor 4 signaling},
journal = {International Immunopharmacology},
year = {2024},
doi = {10.1016/j.intimp.2024.112668}
}
EUVIMED